Pasar al contenido principal

CARACTERIZACION FUNCIONAL DE LAS REGIONES GENETICAS ASOCIADAS A LA ESCLEROSIS SISTEMICA

PID2022-139292OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A holistic approach to understanding immune-mediated inflammatory diseases: bioinformatic tools to integrate omics data

  • Borrego Yaniz, Gonzalo
  • Terrón-Camero, Laura Carmen
  • Kerick, Martin
  • Andrés-León, Eduardo
  • Martin, Javier
Immune-mediated inflammatory diseases (IMIDs) comprise a complex group of pathologies with diverse etiologies and clinical manifestations. In particular, omics technologies have remodeled our understanding of a set of IMIDs such as systemic autoimmune rheumatic diseases (SARDs), generating vast amounts of data on the genome, epigenome, transcriptome, proteome and metabolome of immune cells and SARDs patients. However, the integration of omics data to advance our knowledge of these diseases is challenging, requiring advanced bioinformatic tools. This review explores different multi-omic integrative tools for refining previous research, exploring the biological relevance of datasets within different contexts, or translating omics results into clinical advances. We also discuss relevant multi-omic studies in SARDs research and the potential of omics data from available repositories to complement ongoing investigation in this field., This work supported by the Red de Investigación Cooperativa Orientada a Resultados en Salud, ISCIII (RICOR, RD21/0002/0039) and Grant PID2022-139292OB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”. EA-L was the recipient of a postdoctoral fellowship from the regional Andalusian Government (POSTDOC_20 _00541). LCT-C was also the recipient of a postdoctoral fellowship from the regional Andalusian Government (POSTDOC_21 _00394)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease

  • Rosa-Baez, Carlos
  • Rangel-Pelaez, Carlos
  • Rodríguez-Martín, Inmaculada
  • Kerick, Martin
  • Guillén del Castillo, Alfredo
  • Simeón, Carmen P.
  • Callejas-Rubio, José Luis
  • Voskuyl, Alexandre E.
  • Kreuter, A.
  • Distler, Oliver
  • Proudman, Susanna
  • Nikpour, Mandana
  • Hunzelmann, Nicolas
  • Vries-Bouwstra, Jeska K. de
  • Herrick, A.
  • Allanore, Yannick
  • Beretta, Lorenzo
  • Mayes, Maureen D.
  • Denton, Christopher
  • Assassi, Shervin
  • Martín, Javier
  • Acosta-Herrera, Marialbert
[Objective] The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date., [Methods] Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls., [Results] Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance., [Conclusion] Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the MUC5B promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture., This work was supported by grant PID2022-139292OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU. C.R.B. was supported by the program FPU: [FPU22/01652], funded by the Spanish Ministry of Science Innovation and Universities. C.R.P. was funded by Grant PREP2022-000747 funded by MICIU/AEI /10.13039/501100011033 and by ESF+. I.R.M. was supported by the program FPU: [FPU21/02746], funded by the Spanish Ministry of University. S.A. was supported by R33AR078078, R61AR078078, R01AR081280 and DoDW81XWH-22-1-0162., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon

  • Rangel-Peláez, Carlos
  • Rodríguez-Martín, Inmaculada
  • Rosa Baez, Carlos de la
  • Kerick, Martin
  • Guillén del Castillo, Alfredo
  • Simeón, Carmen P.
  • Callejas-Rubio, José Luis
  • Distler, Oliver
  • Proudman, Susanna
  • Nikpour, Mandana
  • Hunzelmann, Nicolas
  • Moroncini, Gianluca
  • Vries-Bouwstra, Jeska K. de
  • Herrick, A.
  • Allanore, Yannick
  • Alarcón-Riquelme, M. E.
  • Beretta, Lorenzo
  • Mayes, Maureen D.
  • Denton, Christopher
  • Assassi, Shervin
  • Martín, Javier
  • Acosta-Herrera, Marialbert
  • Ortiz-Fernández, Lourdes
  • International SSc Group
  • PRECISESADS Clinical Consortium
  • Australian Scleroderma Interest Group (ASIG)
[Objective] Raynaud’s phenomenon (RP) is the first noticeable symptom of systemic sclerosis (SSc), appearing even years before other signs. Vascular and immune pathways, hallmarks in SSc pathogenesis, are implicated in primary RP. Hence, we aimed to define the shared genetic architecture between these conditions to explore pathogenic mechanisms and whether pleiotropic loci could help identify primary RP patients at increased genetic risk of developing SSc., [Methods] We analysed genome-wide association study (GWAS) summary statistics for primary RP (4 986 cases and 850 981 controls) and SSc (10 654 cases and 18 043 controls). We performed a cross-trait meta-analysis (∼8.6M single nucleotide polymorphisms) to identify variants associated with both diseases. Functional annotation was used to prioritise potential causal genes. We also constructed a polygenic risk score (PRS) to assess clinical implications., [Results] Beyond the well-known HLA associations, we identified five additional pleiotropic loci, including MEOX2 as a novel association for both traits with opposing effects, ADRA2A representing a novel genetic factor for SSc, and IL12A, NFKB1 and TNIP1 as novel loci for primary RP. Functional annotation highlighted vascular and inflammatory pathways. Finally, the PRS model shows modest discrimination (area under the curve = 0.57). However, it allows the identification of primary RP individuals at high genetic risk of developing SSc (75th percentile, relative risk =1.29 [95% CI 1.02, 1.62]; P-value= 3.58 × 10−2)., [Conclusion] This study reveals a genetic link between primary RP and SSc, identifying five novel pleiotropic loci and supporting the potential of genetic profiling for early risk assessment and personalised monitoring strategies., This work was supported by Cooperative Research Networks Oriented to Health Results (RICORS), Inflammatory Diseases Network (REI) (RD21/0002/0039; RD24/0007/0016) from Carlos III Health Institute (ISCIII); grant PID2022-139292OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by FSE+; and by the Innovative Medicines Initiative Joint Undertaking (grant 115565; PRECISESADS project), resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007–2013) and European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution. This research was also supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. L.O.-F. is recipient of a Ramon y Cajal fellowship [RYC2022-036635-I] funded by MICIU/AEI/10.13039/501100011033 and by ESF+. C.R.-B. was supported by the program FPU: [FPU22/01652], funded by the Spanish Ministry of Science Innovation and Universities. I.R.-M. was supported by the program FPU: [FPU21/02746], funded by the Spanish Ministry of University. C.R.-P. was funded by Grant PREP2022-000747 funded by MICIU/AEI/10.13039/501100011033 and by ESF+., Peer reviewed